The authors urge clinicians to balance the use of Immunosuppressant drugs and tocilizumab for COVID-19 patients to avoid the development of infections like Cryptococcemia, leading to death within 30 days.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869327 | PMC |
http://dx.doi.org/10.1002/ccr3.3668 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!